ResearcherJikei University School of MedicineNo recent work listed
Sumiyuki Nishida
Matched on ORCID iD 0000-0003-0137-8649; OpenAlex author ID A5004685668. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 27
2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 2 papers
Papers 4
- Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… Co-author DOI 10.1158/2326-6066.cir-17-0386↗
- Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.8961↗
- Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. Co-author DOI 10.1097/cji.0000000000000020↗
- Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Co-author DOI 10.1007/s00262-011-1033-3↗
Closest collaborators
The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shigeo Koido · 4 shared papers, 2011–2018 · strength 0.17
- Paper Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. DOI 10.3892/ol.2018.8961↗
- Paper Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Ad… DOI 10.1158/2326-6066.cir-17-0386↗
- Paper Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic can… DOI 10.1097/cji.0000000000000020↗
- Haruo Sugiyama · 4 shared papers, 2011–2018 · strength 0.17
- Paper Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. DOI 10.3892/ol.2018.8961↗
- Paper Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Ad… DOI 10.1158/2326-6066.cir-17-0386↗
- Paper Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic can… DOI 10.1097/cji.0000000000000020↗
- Sadamu Homma · 3 shared papers, 2011–2018 · strength 0.11
- Paper Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Ad… DOI 10.1158/2326-6066.cir-17-0386↗
- Paper Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic can… DOI 10.1097/cji.0000000000000020↗
- Paper Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-… DOI 10.1007/s00262-011-1033-3↗
- Hidetoshi Eguchi · 2 shared papers, 2014–2018 · strength 0.09
- Paper Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Ad… DOI 10.1158/2326-6066.cir-17-0386↗
- Paper Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic can… DOI 10.1097/cji.0000000000000020↗
- Hiroaki Nagano · 2 shared papers, 2014–2018 · strength 0.09
- Paper Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Ad… DOI 10.1158/2326-6066.cir-17-0386↗
- Paper Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic can… DOI 10.1097/cji.0000000000000020↗
- Tomoya Kanai · 1 shared paper, 2018 · strength 0.07
- Masato Okamoto · 1 shared paper, 2018 · strength 0.07
- Mikio Kajihara · 1 shared paper, 2018 · strength 0.07
- Shuichi Fujioka · 1 shared paper, 2018 · strength 0.07
- Shigetaka Shimodaira · 1 shared paper, 2018 · strength 0.07
- Zensho Ito · 1 shared paper, 2018 · strength 0.07
- Kazuki Takakura · 1 shared paper, 2018 · strength 0.07
- Masayuki Saruta · 1 shared paper, 2018 · strength 0.07
- Masanori Kon · 1 shared paper, 2018 · strength 0.06
- Hiroaki Yanagimoto · 1 shared paper, 2018 · strength 0.06
- Mari S. Oba · 1 shared paper, 2018 · strength 0.06
- Kei Ito · 1 shared paper, 2018 · strength 0.06
- Shinichi Egawa · 1 shared paper, 2018 · strength 0.06
- Hideaki Shimada · 1 shared paper, 2018 · strength 0.06
- Yoshihide Kanno · 1 shared paper, 2018 · strength 0.06
- Takeshi Ishikawa · 1 shared paper, 2018 · strength 0.06
- Michiaki Unno · 1 shared paper, 2018 · strength 0.06
- Akitaka Takahara · 2 shared papers, 2011–2014 · strength 0.05
- Paper Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic can… DOI 10.1097/cji.0000000000000020↗
- Paper Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-… DOI 10.1007/s00262-011-1033-3↗
- Hisao Tajiri · 2 shared papers, 2011–2014 · strength 0.05
- Paper Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic can… DOI 10.1097/cji.0000000000000020↗
- Paper Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-… DOI 10.1007/s00262-011-1033-3↗
- Yoichi Toyama · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.